Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in the United States.
The patent, number 8,742,088, has been granted by The United States Patent and Trademark Office (USPTO) and covers Scancell’s DNA ImmunoBody® platform technology. This patent is key for the protection of the Company’s pipeline of ImmunoBody® vaccines and follows the grant of counterparts in Australia, China and Japan.
Scancell’s protein ImmunoBody® patent has already been granted in Australia, Canada, Europe, Japan and the United States.
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:
“We are delighted to have further strengthened our IP portfolio around our proprietary ImmunoBody® platform technology. The United States is a key market for us and this, alongside the recent positive results from the Phase 1/2 trial for our SCIB1 ImmunoBody® in melanoma, demonstrates the strong progress Scancell is making. We look forward to continuing development of our ImmunoBody® platform and advancing our SCIB1 clinical trial, bringing patients one step closer to a new treatment for melanoma.”
For Further Information:
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+ 44 (0) 20 3727 1000 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
| Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.